# Aribio completes 52-week phase 3 of oral Alzheimer's candidate AR1001 in 1535 patients

- Published: 2026-11-11 16:21 UTC
- Section: Life & Health › Medicine
- Tags: Aribio AR1001, oral Alzheimer's candidate, phase 3 Alzheimer's trial, CTAD 2026 Boston, topline results, early Alzheimer's disease, 52-week dosing, Fosun Pharma option agreement
- URL: https://realtech.media/news/rt-9c869f942bf186ec734601d9_aribio_completes_52/

**Aribio finished dosing in a global phase 3 trial of oral AR1001 in early Alzheimer's disease across 13 countries; topline results are due at CTAD 2026 in Boston.**

![Aribio completes 52-week phase 3 of oral Alzheimer's candidate AR1001 in 1535 patients](https://realtech.media/media/2026/11/f09c9d31e601873b.jpg)
*Fogarty International Center from Bethesda, MD, Wikimedia Commons, Public domain*

Korean company Aribio has completed the main part of the global phase 3 trial of AR1001, an oral candidate for Alzheimer's disease, according to biz.heraldcorp.com. The company plans to present topline results on the 16th in Boston at the Alzheimer's disease clinical trials conference CTAD 2026. [1] The trial enrolled 1535 patients with early Alzheimer's disease in 13 countries, including the US, European countries, Korea and China. [1]

## Trial design and completion

AR1001 is a synthetic oral candidate designed for once-daily dosing in patients with early Alzheimer's disease. Its development is aimed at protecting neurons in the brain and slowing disease progression. [1]

Over 52 weeks, the AR1001 group was compared with a placebo control group. Of the enrolled patients, 1348 (87.8%) completed the full 52 weeks of dosing. [1] Dosing of the last patient ended on June 29. An extension study assessing long-term safety is now under way, and 95.5% of the patients who completed the main trial are taking part in it. [1]

## Organization and funding

Aribio managed the whole trial itself, from protocol design to oversight of trial sites in each country and of contract research organizations, with its US clinical operations organization at the center. [1] The company financed the phase 3 through regional rights agreements and an option agreement on global rights with China's Fosun Pharma, under which it received payment. [1] The first tranche of a separate equity investment by Fosun Pharma was also paid last month. [1]

## What the CTAD presentation will cover

The primary efficacy endpoint is cognitive function. The data to be presented on the 16th should show how much AR1001 delayed the decline in memory, judgment and the ability to perform daily activities compared with placebo, and whether statistical significance was reached. [1] Safety data from long-term dosing will be presented as well. According to the article, these results will be the key criteria for regulators when they decide on marketing authorization. [1]

## Sources

1. [biz.heraldcorp.com](https://biz.heraldcorp.com/article/10933705)

---

Source: RealTech, realtech.media — https://realtech.media/news/rt-9c869f942bf186ec734601d9_aribio_completes_52/